相关临床试验
323
23 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1996
进行中（未招募）
9
2.8%
已完成
204
63.2%
Enrolling By Invitation
1
0.3%
尚未招募
13
4.0%
招募中
22
6.8%
终止
37
11.5%
撤回
37
11.5%
暂无批准数据
- Researchers at Boston Medical Center and Boston University developed a scalable method to generate CD4+ helper T cells from induced pluripotent stem cells (iPSCs), overcoming a longstanding barrier in stem cell-based immunotherapy. - The protocol relies on removing Notch signaling during later maturation stages while reducing anti-T cell receptor signaling, enabling CD4+ T cells to survive and mature at scale. - The resulting T cells resemble those from blood with a full repertoire of subtypes, and the team's next step is to introduce a chimeric antigen receptor (CAR) and test cancer-killing ability in animal models. - The advance could support off-the-shelf CAR-T therapies that are ready when a patient is diagnosed, eliminating cell collection and individualized manufacturing.
- The HER Salt Lake Contraceptive Initiative found that when patients receive person-centered counseling and robust access support, failure rates across most birth control methods narrow to approximately 1 pregnancy per 100 participants per year. - The three-year study of over 4,000 participants challenges the long-held assumption that long-acting reversible contraceptives are vastly superior to shorter-term methods like pills or rings. - Researchers emphasize that respecting patient preferences, providing timely access, and removing logistical barriers are critical to improving real-world contraceptive effectiveness. - The findings suggest that patient-centered care can make preferred methods both acceptable and highly effective, reducing the perceived trade-off between liking a method and needing reliable pregnancy prevention.
- UCLA and UC Davis will co-lead the PRISM Trial, a $16 million randomized controlled study evaluating artificial intelligence support for mammogram interpretation across seven academic medical centers. - The study represents the first large-scale randomized trial of AI in breast cancer screening in the United States, involving hundreds of thousands of mammograms across California, Florida, Massachusetts, Washington, and Wisconsin. - Researchers aim to determine whether AI tools help radiologists detect more cancers or simply increase false positives, addressing a critical evidence gap as AI-assisted mammograms become increasingly common in clinical practice. - The patient-centered trial will maintain routine screening procedures while randomly assigning mammograms to be interpreted either by radiologists alone or with FDA-cleared AI assistance from Transpara by ScreenPoint Medical.
- A comprehensive analysis of insulin out-of-pocket costs and usage patterns from 2008-2021 reveals persistent disparities in insulin access between higher-income and lower-income patients with diabetes. - Insulin costs peaked between 2014-2017 before stabilizing and declining by 2021, with corresponding changes in prescription fills, but income-based gaps remained consistent throughout the study period. - Lower insulin use among disadvantaged populations leads to both immediate complications requiring emergency care and long-term organ damage, significantly increasing healthcare system costs. - High-deductible health plans with savings options particularly impact insulin accessibility, as patients face higher out-of-pocket expenses for this life-sustaining medication.
- Advancements in joint replacement techniques now allow patients to begin walking the same day as surgery, with most returning home within 24 hours of the procedure. - Multi-modal pain management approaches combine low-dose medications, reducing reliance on opioids while effectively managing post-surgical discomfort. - Most patients can return to low-impact activities within 6-12 weeks, with joint replacements typically lasting 15-20 years before requiring revision.
- Colorectal cancer rates among young adults under 50 have increased in 27 out of 50 countries worldwide, with New Zealand, Chile, and Puerto Rico showing the highest annual growth rates of approximately 4%. - The American Cancer Society reports a 2.4% annual increase in colon cancer rates among people under 50 between 2012 and 2021, even as cases decline in older populations, prompting screening guidelines to lower the recommended age from 50 to 45. - Medical experts emphasize the importance of recognizing early symptoms such as changes in bowel habits, rectal bleeding, abdominal pain, and unexplained weight loss, as younger patients often attribute these symptoms to stress or diet, leading to delayed diagnosis.
- Dr. Geoff Oxnard, CMO at Blossom Hill Therapeutics and thoracic oncologist at Boston Medical Center, is spearheading research on novel EGFR inhibitors to combat treatment resistance. - Advancements in precision medicine are highlighting the critical importance of early cancer detection, potentially revolutionizing treatment outcomes. - Dr. Oxnard demonstrates how dual roles in clinical practice and industry can enhance patient-centered care development and delivery.
- A recent study reveals that racial and ethnic diversity in head and neck cancer clinical trials in the U.S. has worsened over the past decade. - The research highlights a critical disparity, indicating that race and gender can significantly impact a patient's access to potentially life-saving cancer treatments. - Boston Medical Center initiatives show promise, achieving 58% participation from underrepresented groups in head and neck cancer trials, contrasting with national averages of 7-12%. - Researchers emphasize the urgent need for novel strategies to enhance inclusivity in clinical trials, ensuring equitable access to effective treatments for all patients.
